Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability of Laroprovstat/Rosuvastatin Fixed Combination in Healthy Adults
NCT07316608Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2026
- Primary completion
- Jun 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of laroprovstat and rosuvastatin in hypercholesterolemia (7 cohorts), sponsored by AstraZeneca. Primary endpoints: Area under concentration time curve from time 0 to infinity, Area under concentration curve from time 0 to the last quantifiable concentration and 1 more. Started Mar 2026; status: completed.
02
Drugs
laroprovstatrosuvastatin
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT07316608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07316608.